Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Arrowhead Pharmaceuticals (ARWR) as of Nov 3, 2026 is -9,619.01 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 100.81 % — a change of -9,642.18% (lower).

FCF Conversion

-9,619.01 %

YoY

-9,642.18%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Arrowhead Pharmaceuticals is 2025 -9,619.01 % . FCF Conversion Rate (FCF/EBITDA) of Arrowhead Pharmaceuticals was 2024 100.81 % . It decreases by -9,642.18% lower compared to the previous year.

The Arrowhead Pharmaceuticals FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
89.34 USD
Jan 1, 2019
236.90 USD
Jan 1, 2020
127.44 USD
Jan 1, 2021
-104.90 USD
Jan 1, 2022
107.03 USD
Jan 1, 2023
161.07 USD
Jan 1, 2024
100.81 USD
Jan 1, 2025
-9,619.01 USD
The Arrowhead Pharmaceuticals FCF Conversion history
YEARFCF ConversionYoY
-9,619.01 %-9,642.18%
100.81 %-37.41%
161.07 %+50.48%
107.03 %-202.04%
-104.90 %-182.31%
127.44 %-46.21%
236.90 %+165.18%
89.34 %-3.59%
92.66 %+10.89%
83.56 %+13.52%
73.61 %+16.22%
63.34 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Arrowhead Pharmaceuticals Stock analysis

What does Arrowhead Pharmaceuticals do? Arrowhead Pharmaceuticals Inc is a biotechnology company that develops and commercializes RNA-based therapeutics. The company is headquartered in Pasadena, California and was founded in 2007. Arrowhead's history began when a group of scientists at the University of Texas came together to work on the development of RNA-based therapeutics. In 2007, Arrowhead was established and the company's patented TRiM™ (Targeted RNAi Molecules) technology was developed to specifically overcome barriers in RNAi-based therapeutics. The company is divided into several divisions, including Hepatitis B, cardiovascular, metabolic disorders, and oncology. Arrowhead has developed a range of RNAi-based investigational products, including ARC-520, which is being developed for the treatment of Hepatitis B and is currently in clinical trials. ARC-520 is designed to inhibit the formation and release of viral particles in liver cells, thereby halting the progression of the disease. Arrowhead has also developed products for the treatment of life-threatening diseases such as Alpha-1 Antitrypsin Deficiency (AAT) and hypertriglyceridemic pancreatitis (HTG). The treatments offered by Arrowhead aim to utilize RNA in disease treatment where other methods have failed. Arrowhead Pharmaceuticals Inc's business model is based on the discovery, development, and commercialization of RNAi-based therapeutics. The company collaborates with partners to accelerate the development and commercialization of its products. Arrowhead has a strategic partnership with Johnson & Johnson Pharmaceuticals Research & Development, LLC. Arrowhead Pharmaceuticals Inc is listed on the NASDAQ stock exchange under the ticker symbol ARWR. The company employs approximately 150 employees, including scientists, researchers, and specialists specialized in RNA biology. Recently, Arrowhead Pharmaceuticals Inc partnered with Takeda Pharmaceutical Co. Ltd. to develop RNAi-based therapeutics. This partnership aims to accelerate the development of RNAi-based therapeutics and optimize the company's potential in the field of RNA biology. In summary, Arrowhead Pharmaceuticals is a biotechnology company specializing in RNA biology. The company has developed a patented TRiM™ technology that specifically overcomes barriers in disease therapy with RNAi-based therapeutics. Arrowhead has developed several products for the treatment of life-threatening diseases and collaborates with partners to accelerate the development of its products and optimize commercialization. Arrowhead Pharmaceuticals Inc is an innovative player in the biotechnology field and strives to improve and revolutionize the common practice of RNAi-based therapeutics. Arrowhead Pharmaceuticals is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Arrowhead Pharmaceuticals stock

FCF Conversion Rate (FCF/EBITDA) of Arrowhead Pharmaceuticals is -9,619.01 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Arrowhead Pharmaceuticals changed from 100.81 % to -9,619.01 %, representing a -9,642.18% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Arrowhead Pharmaceuticals since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Arrowhead Pharmaceuticals with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Cash Flow — Arrowhead Pharmaceuticals

Operating Cash FlowCapital ExpendituresFree Cash FlowFCF per ShareDividends PaidShare BuybacksInvesting Cash FlowFinancing Cash FlowCapEx / RevenueCash Flow per ShareStock-Based CompensationChange in Working CapitalAcquisitions (Net)Net Change in CashCapEx/OCFFCF/Net IncomeFCF ConversionCash ConversionTotal Shareholder PayoutCapEx/D&A

All Key Metrics — Arrowhead Pharmaceuticals